Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

NCT05222516 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

63

Enrollment

INDUSTRY

Sponsor class

Stopped Recommendation of DSMB (futility of Endpoints)

Conditions

Atopic Dermatitis

Interventions

DRUG: Broncho-Vaxom
DRUG: Placebo

Sponsor

OM Pharma SA